This analysis examines the 2021 NCCN guidelines for adjuvant systemic therapy in early-stage hormone receptor-positive, HER2-negative breast cancer. The updated recommendations reflect recent evidence on risk stratification and treatment efficacy. Key modifications include refined criteria for identifying patients who may benefit from adjuvant chemotherapy and endocrine therapy intensification. This review synthesizes the current evidence and guideline updates, providing a framework for clinicians to optimize management strategies for this patient population, ultimately informing personalized treatment decisions and improving patient outcomes.